Declaration of conflict of interest
|
|
|
- Irene McBride
- 5 years ago
- Views:
Transcription
1 Declaration of conflict of interest Claudio Borghi Lectures fees: Menarini International, Servier International, Recordati International, Ely-Lilly USA, BMS, Boheringer Ingelheim, Novartis Pharma Research grant: Menarini International, Novartis Pharma Membership Scientific Commitees: Ely-Lilly, Menarini International, Institute de Reseach Servier, Novartis Pharma, Takeda Pharmaceuticals
2 Pharmacotherapy for CV disease in pregnancy. Antihypertensive therapy Claudio Borghi, F.A.H.A, F.E.S.C. Department of Medical and Surgical Sciences University of Bologna Bologna, Italy
3
4 ESH Guidelines, Eur Heart J 2011
5 HYPERTENSION IN PREGNANCY Epidemiology Most common medical disorder in pregnancy* Overall complicates 6-8% of all pregnancies* Its prevalence is progressively increasing (age, other RF s)* Responsible for an increase in maternal/perinatal mortality and morbidity* Responsible for the 12.3% of all pregnancy-related maternal deaths ** From N.H.B.P.E.P. Working Group on HBP in Pregnancy, Am J Obstet Gynecol, 2000, (mod) ** From Berg Cj et al, Obstet Gunecol 2010
6 The treatment of hypertension in pregnancy 1. Should we reduce blood pressure?
7
8 Effects of less vs. more tight BP control in patients with mild-to-moderate hypertension in pregnancy. The Control of Hypertension In Pregnancy Study-Pilot Less Tight BP control (n.66) Tight BP control (n.66) Average DBP difference (mmhg) -3.5 (-6.4 / - 0.6) Post-randomization antihypertensive treatment 69.7% 89.2% Proteinuria 24.2 % 30.8% Severe hypertension 57.6% 40.0% Serious maternal complication 4.6% 3.1% Preterm birth 36.4% 40.0% Birthweight (kg) 2675 ± ± 855 Magee LA el al, BJOG 2007
9 The treatment of hypertension in pregnancy 1. Should we reduce blood pressure? 2. Which one is the goal of treatment?
10 The stated goals of treating HBP during pregnancy are the same among the different guidelines : - prevention of maternal stroke - prevention of maternal target organ damage - prevention of other CV complications - fetal protection
11 The treatment of hypertension in pregnancy 1. Should we reduce blood pressure? 2. Which one is the goal of treatment? 3. Who should be treated?
12 CWG Redman BMJ 2011
13 Reasons not supporting the antihypertensive treatment in mild-moderate HBP in pregnancy. Non significant maternal benefit - young age of most patients - brief duration of hypertension Increased fetal risk - impaired utero-placental perfusion - exposure to medication with potential AE s
14 UTERO-PLACENTAL DOPPLER VELOCIMETRY AND BLOOD PRESSURE IN PATIENTS WITH PRE-ECLAMPSIA TREATED WITH NIFEDIPINE-GITS OR METHYLDOPA Blood Pressure Uterine Artery Resistance Index *,** p<0.005 vs Baseline * ** p<0.05 vs Baseline p<0.05 vs N * * ** * Borghi C et al J Hypertension 2003
15 Kaplan-Meier plots of cumulative probability of being free of HTN, CHD, and stroke among nulliparous women, those with history of normotensive pregnancy, and women with a history of either hypertensive or preeclamptic pregnancy p = vs normo p< vs normo p = vs normo p < vs normo p< vs normo p= vs normo HTN, hypertension CHD, coronary heart disease Garovic VD et Al., J Hypertens 2010;28(4):
16 Proposal for a more extensive approach to the treatment of HBP in pregnancy Condition Treatment strategy Management Chronic Hypertension (pre-pregnancy) De-novo hypertension >20 weeks, BP 140/90 mmhg Continue medications other than ACEI/ARB s Specific anti-hbp therapy (Methyldopa, CCB s, β- blockers, diuretics, hydralazine) Monitor drug dosage during first and second trimester and adapt to manage BP < 140/90 mmhg Close follow-up for the development of pre-eclampsia and fetal monitoring Moser M et al J Hypertension 2012
17 The treatment of hypertension in pregnancy 1. Should we reduce blood pressure? 2. Which one is the goal of treatment? 3. Who should be treated? 4. Which antihypertensive drugs?
18 Criteria for the choice of antihypertensive drugs in pregnancy The choice of antihypertensive drugs for the treatment of hypertension in pregnancy is limited to those drugs that: - Have long been in clinical use - Have been proven to be effective in BP control - Have been relatively well tolerated - Have side-effects profile considered tolerable by obstetricians
19 FIRST-LINE DRUGS FOR THE LONG-TERM, ORAL TREATMENT OF HYPERTENSION DURING PREGNANCY Drug Starting dose Maximum dose Safety profile Methyldopa 250 mg bid 4 g/day Good Labetalol 100 mg bid 2400 mg/day Good (fetal growth restriction) Nifedipine 30 mg oid 60 mg /day Good (no Mg ++ sulphate) Verapamil 120 mg bid 360 mg/day Good ß-blockers Variable Variable Low birth weight Neonatal bradicardia Diuretics 12.5 mg oid 50 mg/day Contraindicated in PE BP control in Chronic HBP ACEI, ARB s, DRI / / Absolutely contraindicated National High Blood Pressure Education Program Working Group, 2000 Sibai BM, Obstet Gynecol 2003, Podymow T, Hypertension 2008
20 The use of antihypertensive drugs in pregnancy: the ESH-ESC Guidelines In non-severe HBP and out-of-emergency situations, methyldopa, labetalol and CCB s are the preferred drugs. Atenolol should be given with caution because of reports of fetal growth retardation. Unless there is oliguria, diuretic therapy is inappropriate in pre-eclampsia. ACEI and ARB s (DRI) should never been used in hypertension ESH-ESC Guidelines, J Hypertens 2007
21
22 Antihypertensive drugs in patients with hypertension during pregnancy ESC Guidelines on the management of CV diseases in pregancy, Eur Heart J 2011
23 Drugs for the treatment of hypertension in pregnancy according to ASH and FDA Lindheimer MD et al, J Am Soc Hypertens 2008
24 Antihypertensive medication and pregnancy Centrally-acting agents Preferred Methyldopa Proven safety and efficacy Depression, liver problem, limited efficacy in BP control Alternative Clonidine As methyldopa Limited data on fetal safety Beta-blockers Preferred Labetalol Similar but more effective than methyldopa Contraindicated Atenolol N/A IUGR CCB s Preferred Nifedipine Similar but more effective than methyldopa Neonatal hypoglycemia with high doses Interaction with magnesium Alternative Verapamil Similar efficacy as other agents As nifedipine + bradycardia Direct vasodilators Hydralazine Efficacious i.v. (?) Poor safety profile Nitroprussid e Only for life-threatning severe HBP Poor safety profile Diuretics Thiazide Useful in chronic HBP Volume contraction, electrolyte disturbances (PE?) Moser M et al J Hypertension 2012 Podymov T et al, Hypertension 2008
25 Current international trials for HBP in pregnancy Trial Patients Drugs Control of Hypertension In Pregnancy Study (CHIPS) All More vs. less aggressive BP control Goal-directed Therapy in Pregnant Women at High Risk of Developing Pre-eclampsia Treatment Targets for Chronic Hypertension in Pregnancy Antihypertensive Treatment in Stable Pregnant Women with Severe Per-eclampsia Hydralazine Versus Labetalol for the Management of Hypertensive Disorders of Pregnancy High-risk pregnancy Chronic HBP Preeclampsia Hypertensive crisis Nifedipine vs. Labetalol Methyldopa vs. Labetalol vs. Nifedipine vs. Clonidine Labetalol vs. Hydralazine Labetalol vs. Hydralazine ClinicalTrial.gov, 2012 WHO ICTRP, 2012
26 2007 ESH-ESC Guidelines: Hypertension in pregnancy: Emergency situations Under emergency circumstances, intravenous labetalol and oral nifedipine are indicated. Intravenous hydralazine is no longer the drug of choice because of an excess of perinatal adverse effects. Intravenous infusion of sodium nitroprusside is useful in hypertensive crises, but prolonged administration should be avoided (fetal cyanide poisoning) ESH-ESC Guidelines, Journal of Hypertension 2007;25:
27 Drugs for the urgen control of severe HBP in pregnancy according to ASH and ACOG Lindheimer MD et al, J Am Soc Hypertens 2008
28 The treatment of hypertension in pregnancy 1. Should we reduce blood pressure? 2. Which one is the goal of treatment? 3. Who should be treated? 4. Which antihypertensive drugs? 5. What else should be done?
29 Therapeutic approaches to treating HTN in pregnancy Potential new targets for the treatment of preeclampsia: Adenosine, L-arginine and NO (ALANO) pathway Heme oxygenase-1 pathway Endothelin-1 pathway Recombinant angiogenic factors AT1 receptor agonistic autoantibodies Drugs with anti-inflammatory actions Genetic approaches L-carnitine? Mod. from Mate A et Al, Drug Discovery Today 2012
30
31 LV diastolic dysfunction LV functional/geo metrical abnormalities LV global remodelling/hypertroph y Melchiorre K et al, Hypertension 2011
32 Effects of nifedipine GITS and methyldopa on LV structure and function in patients with preeclampsia LVESV LVEDV LVEF P<0.01 P<0.01 Borghi C et al J Hypertens 2004
33 Le due Fride, Frida Khalo, 1939
MANAGEMENT OF HYPERTENSION IN PREGNANCY, THE ALGORHITHM
MANAGEMENT OF HYPERTENSION IN PREGNANCY, THE ALGORHITHM Are Particular Anti-hypertensives More Effective or Harmful Than Others in Hypertension in Pregnancy? Existing data is inadequate Methyldopa and
CHAPTER 12 HYPERTENSION IN SPECIAL GROUPS HYPERTENSION IN PREGNANCY
CHAPTER 12 HYPERTENSION IN SPECIAL GROUPS HYPERTENSION IN PREGNANCY v Mild preeclampsia is managed by close observation of the mother and fetus preferably in hospital. If the diastolic blood pressure remains
Based on 2014 SOGC Guidelines
Based on 2014 SOGC Guidelines 22nd Edition 2015 1 ICH + gestational hypertension by far the biggest cause of direct maternal deaths New stats coming in 2013 OCR 22nd Edition 2015 2 Diastolic 90 mmhg is
Hypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
Should hypertensive disorders of pregnancy be considered as a prehypertension state?
February 2018 Should hypertensive disorders of pregnancy be considered as a prehypertension state? Pr. Jacques Blacher Paris-Descartes University ; AP-HP ; Unité HTA, prévention et thérapeutique cardio-vasculaires,
Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs
Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs Blood Pressure Normal = sys
AWHONN Oregon Section 2014
AWHONN Oregon Section 2014 Carol J Harvey, MS, BSN, RNC-OB, C-EFM, CS Northside Hospital Atlanta Cherokee - Forsyth Hypertensive in Pregnancy Carol J Harvey, MS, RNC-OB, C-EFM Clinical Specialist Northside
CMQCC Preeclampsia Tool Kit: Hypertensive Disorders Across the Lifespan
CMQCC Preeclampsia Tool Kit: Hypertensive Disorders Across the Lifespan Carol J Harvey, MS, BSN, RNC-OB, C-EFM, CS Northside Hospital Atlanta Cherokee - Forsyth New! Improving Health Care Response to Preeclampsia:
Hypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg
Hypertension diagnosis (see detail document) Non-diabetic Diabetic Very elderly (older than 80 years) Target less than 140/90mmHg Target less than 130/80mmHg Consider SBP target less than 150mmHg Non-diabetic
Policy REVISED: 6/30/2016 3:30 PM. Applies To: ObGyn Responsible Department: ObGyn Revised: June 30, 2016
Title: Antihypertensive Treatment for Severe Hypertension During Pregnancy Applies To: ObGyn Responsible Department: ObGyn Revised: June 30, 2016 Policy POLICY STATEMENT: Pregnant or postpartum patients
Incidental Findings; Management of patients presenting with high BP. Phil Swales
Incidental Findings; Management of patients presenting with high BP Phil Swales Consultant Physician Acute & General Medicine University Hospitals of Leicester NHS Trust Objectives The approach to an incidental
Counseling and Long-term Follow up After Gestational Disorders
Counseling and Long-term Follow up After Gestational Disorders Tanya Melnik, MD Assistant Professor, University of Minnesota Sarina Martini, MD Ob/Gyn Resident, PGY4 University of Minnesota Counseling
LEARNING OBJECTIVES 2/20/2017
HYPERTENSION IN PREGNANCY: PREVENTING SEVERE MATERNAL MORBIDITY & MORTALITY THROUGH THE IMPLEMENTATION OF EVIDENCED BASED PROTOCOLS Laura Senn, RN, PhD, CNS Sutter Medical Center, Sacramento LEARNING OBJECTIVES
Stroke in Pregnancy. Stroke in Pregnancy 6/23/13
G5#$#Preven*ng#Maternal#Morbidity#and#Mortality#Via# Expanded#Scope#of#Nursing#Prac*ce#As#First#Responder# in#hypertensive#crisis#of#preeclampsia# The$presenter$reports$no$relevant,$influencing$financial$rela5onships.$
Antihypertensive drugs: I. Thiazide and other diuretics:
Clinical assessment of hypertensive patient: You have to take history regarding the presence of other risk factors for CAb like diabetes mellitus, smoking, etc. Take history whether the patient takes medications
Reframe the Paradigm of Hypertension treatment Focus on Diabetes
Reframe the Paradigm of Hypertension treatment Focus on Diabetes Paola Atallah, MD Lecturer of Clinical Medicine SGUMC EDL monthly meeting October 25,2016 Overview Physiopathology of hypertension Classification
Outcomes of Pregnancies at Risk for Hypertensive Complications Managed Using Impedance Cardiography
Outcomes of Pregnancies at Risk for Hypertensive Complications Managed Using Impedance Cardiography David G. Chaffin, M.D., 1 and Denise G. Webb, RNC, BSN 2 ABSTRACT We assessed the effect of antihypertensive
How clinically important are the results of the large trials in hypertension?
How clinically important are the results of the large trials in hypertension? Stéphane LAURENT, MD, PhD, FESC Pharmacology Department and PARCC / INSERM U970 Hôpital Européen Georges Pompidou, Université
You admitted a previously healthy nullipara at 36 weeks gestation who presented with new-onset periorbital edema and is found to have blood pressure
Preeclampsia Case report You admitted a previously healthy nullipara at 36 weeks gestation who presented with new-onset periorbital edema and is found to have blood pressure readings of 150/100 to 155/105
Postpartum hypertension, preeclampsia and eclampsia. Arun Jeyabalan, MD MS University of Pittsburgh
Postpartum hypertension, preeclampsia and eclampsia Arun Jeyabalan, MD MS University of Pittsburgh Confusing concept Preeclampsia only occurs in pregnancy placenta is required Delivery cures preeclampsia
Masked Hypertension. Why Should We Care? Dr. Peter J. Lin Director Primary Care Initiatives - Canadian Heart Research Centre
Masked Hypertension Why Should We Care? Dr. Peter J. Lin Director Primary Care Initiatives - Canadian Heart Research Centre PRESENTER DISCLOSURE Faculty: Dr. Peter Lin Relationships with commercial interests:
Hypertensives Emergency and Urgency
Hypertensives Emergency and Urgency Budi Yuli Setianto Cardiology Divisision Department of Internal Medicine Faculty of Medicine UGM Sardjito Hospital Yogyakarta Background USA: Hypertension is 30% of
Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension
Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk
MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
SBP in range of 120 to 140 :no progression or regression of CAD. Sipahi et al., 2006
Management of Hypertension in Patients with CAD M. Mohsen Ibrahim, MD Cardiology Department- Cairo University 1. What is the optimal BP in patients with hypertension and CAD? 2. What is the minimum safe
7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension
Prevalence of Hypertension Hypertension: Diagnosis and Management T. Villela, M.D. Program Director University of California, San Francisco-San Francisco General Hospital Family and Community Medicine
HST 071. IN SUMMARY PREGNANCY INDUCED HYPERTENSION Classification of Hypertensive Disorders of Pregnancy
Harvard-MIT Division of Health Sciences and Technology HST.071: Human Reproductive Biology Course Director: Professor Henry Klapholz IN SUMMARY Classification of Hypertensive Disorders of Pregnancy HST
Heart Failure treatment during pregnancy
Heart Failure treatment during pregnancy Angeles Alonso García Hospital Universitario Puerta de Hierro. Majadahonda. Madrid. Spain European Society of Cardiology. Stockholm. 29 August 2010 Starting Point
ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
Hypertension (JNC-8)
Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint
CONTROL OF BLOOD PRESSURE IN PREGNANCY: HOW HIGH IS TOO HIGH? EVELYNE REY, CHU Ste-Justine, Montreal
CONTROL OF BLOOD PRESSURE IN PREGNANCY: HOW HIGH IS TOO HIGH? EVELYNE REY, CHU Ste-Justine, Montreal CONFLICTS OF INTEREST $: None Others: Canadian guidelines, CHIPS CSIM2015 2 LEARNING OBJECTIVES New
HTN of pregnancy is serious and must be controlled, because without monitoring it can develop into pre-eclampsia and finally to eclampsia.
Sheet Pharmacology #7 1 Antihypertensive drugs of pregnancy: ببسسممم الله االرححممننن االرححيممم Usage of normal drugs of chronic HTN is controversial in pregnancy, because after few weeks or second trimester,
Hypertension Putting the Guidelines into Practice
Hypertension 2017 Putting the Guidelines into Practice Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or
Preeclampsia: What s old is new again. Gene Chang, MD Maternal Fetal Medicine
Preeclampsia: What s old is new again Gene Chang, MD Maternal Fetal Medicine Objectives Define Preeclampsia Review current guidelines Role of proteinuria Timing of delivery Seizure prevention Severe Hypertension
Clinical features. Abnormal vasculogenesis and angiogenesis and releasing of antiangiogenic
Clinical features Abnormal vasculogenesis and angiogenesis and releasing of antiangiogenic factors results in Vasospasm Endothelial dysfunction Etiology of various clinical signs and symptoms So, Preeclampsia
Hypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
Treating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
INTRAVENOUS HYDRALAZINE POLICY
PURPOSE INTRAVENOUS HYDRALAZINE POLICY The purpose of this policy is to: provide safe and effective care for women establish a local approach to care that is evidence based and consistent inform good decision
Pre-ALLHAT Drug Use. Diuretics. ß-Blockers. ACE Inhibitors. CCBs. Year. % of Treated Patients on Medication. CCBs. Beta Blockers.
Pre- Drug Use % of Treated Patients on Medication 60 50 40 30 20 10 0 1978 Diuretics ß-Blockers ACE Inhibitors Year CCBs CCBs Beta Blockers Diuretics ACE Inhibitors 1980 1982 1984 1986 1988 1990 1992 IMS
Section 3, Lecture 2
59-291 Section 3, Lecture 2 Diuretics: -increase in Na + excretion (naturesis) Thiazide and Related diuretics -decreased PVR due to decreases muscle contraction -an economical and effective treatment -protect
JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
Hypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015
Hypertension Update Beverly J. Mathis, D.O. OOA May 2015 Objectives Learn new recommendations for BP treatment goals Approach to hypertension in the office Use of hypertensive drugs, and how to tailor
Magnesium sulfate has an antihypertensive effect on severe pregnancy induced hypertension
Hypertension Research In Pregnancy 11 S. Takenaka et al. ORIGINAL ARTICLE Magnesium sulfate has an antihypertensive effect on severe pregnancy induced hypertension Shin Takenaka 1, Ryu Matsuoka 2, Daisuke
By Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
Management of Hypertension. Ahmed El Hawary MD Suez Canal University
Management of Hypertension Ahmed El Hawary MD Suez Canal University Minimal vs. Optimal Care Resources more than science affect type of care and level of management. what is possible (minimal care) and
Management of Hypertension in special groups. DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University
Management of Hypertension in special groups BY DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University AGENDA SPECIAL GROUPS SPECIFIC DRUDS FOR SPECIAL GROUPS TARGET BP FOR SPECIAL GROUPS:
Management of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
Egyptian Hypertension Guidelines
Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich
Difficult to Treat Hypertension
Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic
Insidie del binomio iperuricemia e rischio CV
Insidie del binomio iperuricemia e rischio CV Claudio Borghi, FESC, FAHA Department of Medical and Surgical Sciences University of Bologna, Bologna, Italy Claudio Borghi Potential conflicts of interest
Tocolytics. Tocolytics (terbutaline, magnesium sulfate injection) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.06 Subject: Tocolytics Page: 1 of 5 Last Review Date: September 15, 2016 Tocolytics Description Tocolytics
Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017
Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017 The most important reason for treating hypertension in primary care is to prevent
Practical Aspects of Hypertension: Simple Strategies to Help You and Your Patients Meet Guideline Blood Pressure Targets
Practical Aspects of Hypertension: Simple Strategies to Help You and Your Patients Meet Guideline Blood Pressure Targets Robert J. Herman University of Calgary herman@ucalgary.ca Conflict of Interest Disclosure
TREATMENT OF HYPERTENSION
TREATMENT OF HYPERTENSION Aim of treatment BP Goals Main items of treatment Lifestyle modification When to start drug Rx Pharmacological therapy 1. Relief of symptoms 2. Prevention of complications and
HYPERTENSION IN EMERGENCY MEDICINE Michael Jay Bresler, M.D., FACEP
HYPERTENSION IN EMERGENCY MEDICINE Michael Jay Bresler, M.D., FACEP What is normal blood pressure? Prehypertension 130-139/80-90 Compared with normal BP Double the risk for developing hypertension. Lifestyle
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
Managing Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park.
Managing Hypertension in Diabetes 2015 Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park Case Scenario Mike M is a 59 year old man with type 2 diabetes managed
Byvalson. (nebivolol, valsartan) New Product Slideshow
Byvalson (nebivolol, valsartan) New Product Slideshow Introduction Brand name: Byvalson Generic name: Nebivolol, valsartan Pharmacological class: Beta-blocker + angiotensin II receptor blocker (ARB) Strength
Tailoring treatment to risk
OBG MANAGEMENT COVER ARTICLE Hypertension in pregnancy Tailoring treatment to risk BY BAHA M. SIBAI, MD, and MARK CHAMES, MD Not all hypertensive gravidas should receive drug therapy. In fact, antihypertensive
Hypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
Hypertension in Pregnancy. Dr Jenny Myers PhD MRCOG Senior Lecturer, Consultant Obstetrician St Mary s Hospital
Hypertension in Pregnancy Dr Jenny Myers PhD MRCOG Senior Lecturer, Consultant Obstetrician St Mary s Hospital Maternal Mortality report 2006-8 Pre-eclampsia/eclampsia 2 nd highest cause of direct maternal
ADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
Hypertension 2015: Recent Evidence that Will Change Your Practice
Hypertension 2015: Recent Evidence that Will Change Your Practice Gerald W. Smetana, M.D. Division of General Medicine Beth Israel Deaconess Medical Center Professor of Medicine Harvard Medical School
ADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
Explore the Rationale for the Dual Mechanism CCB/ARB Approach in Hypertension Management
Explore the Rationale for the Dual Mechanism CCB/ARB Approach in Hypertension Management Jeong Bae Park, MD,PhD Dept of Med/Cardiology, Cheil General Hospital, Kwandong University College of Medicine Apr
Thiazide or Thiazide Like? Choosing Wisely Academic Detailing Conference Digby Pines October 12-14
Thiazide or Thiazide Like? Choosing Wisely Academic Detailing Conference Digby Pines October 12-14 Disclosures Pam McLean-Veysey, Team Leader Drug Evaluation Unit DEU funded by the Drug Evaluation Alliance
PRE GESTATIONAL DIABETES. Conflicts
PRE GESTATIONAL DIABETES Christopher Goodier, MD Assistant Professor, Maternal Fetal Medicine Medical University of South Carolina Conflicts I have no relevant disclosures or conflict of interest with
Introduction. Factors affecting blood pressure: 1-COP = HR X SV mainly affect SBP. 2-TPR = diameter of arterioles X viscosity of blood affect DBP
Introduction Hypertension is a persistent elevation of blood pressure above 140 / 90 mmhg for more than three sitting. (0ptimal level
Hypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
Hypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)
Practice Guidelines and Principles: Guidelines and principles are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines and principles should be followed
ESC Guidelines on the Management of Cardiovascular Diseases during Pregnancy
ESC Guidelines on the Management of Cardiovascular Diseases during Pregnancy Task force on the management of CVD during pregnancy of the ESC Chair: Vera Regitz-Zagrosek, Charite, Berlin None DECLARATION
ANGIOTENSIN RECEPTOR BLOCKERS ARE FIRST LINE TREATMENT : PRO
ANGIOTENSIN RECEPTOR BLOCKERS ARE FIRST LINE TREATMENT : PRO Prof Xavier Girerd M.D., Ph.D., F.E.S.C. Endocrinology Department Cardiovascular Prevention Unit Groupe Hospitalier Pitié-Salpêtrière Faculté
What s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
Hypertension CHAPTER-I CARDIOVASCULAR SYSTEM. Dr. K T NAIK Pharm.D Associate Professor Department of Pharm.D Krishna Teja Pharmacy College, Tirupati
CHAPTER-I CARDIOVASCULAR SYSTEM Hypertension SUB: PHARMACOTHERAPEUTICS-I CODE:T0820006 Dr. K T NAIK Pharm.D Associate Professor Department of Pharm.D Krishna Teja Pharmacy College, Tirupati Hypertension
Hypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital
Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment
Agonistic Autoantibodies to Angiotensin II Type I Receptor Contributes Partly to Placental Ischemia-Induced Cerebrovascular Abnormalities
Agonistic Autoantibodies to Angiotensin II Type I Receptor Contributes Partly to Placental Ischemia-Induced Cerebrovascular Abnormalities Junie Paula Warrington 1, Fan Fan 1, Babbette B. LaMarca 1, Ralf
HYPERTENSION: Sustained elevation of arterial blood pressure above normal o Systolic 140 mm Hg and/or o Diastolic 90 mm Hg
Lecture 39 Anti-Hypertensives B-Rod BLOOD PRESSURE: Systolic / Diastolic NORMAL: 120/80 Systolic = measure of pressure as heart is beating Diastolic = measure of pressure while heart is at rest between
Categories of HTN. Overview of Hypertension. Types of Hypertension
Categories of HTN Overview of Hypertension Normal SBP 100 Quick review of the Basics: What is
The dos and don ts των νέων Κατευθυντηρίων Οδηγιών της Ευρωπαϊκής Καρδιολογικής Εταιρείας Για την καρδιαγγειακή νόσο στην εγκυμοσύνη
The dos and don ts των νέων Κατευθυντηρίων Οδηγιών της Ευρωπαϊκής Καρδιολογικής Εταιρείας Για την καρδιαγγειακή νόσο στην εγκυμοσύνη Θωμάς Κ. Μακρής, MD FA, FES Συντονιστής Διευθυντής Καρδιολογικού Τμήματος
Disclosure of Relationships past 12 months
HYPERTENSION IN WOMEN: WHAT ARE THE IMPLICATIONS OF THE NEW HYPERTENSION GUIDELINES? ANGELA L. BROWN, MD Associate Professor of Medicine // Cardiovascular Division Washington University School of Medicine
Comparison of Efficacy and Safety of Intravenous Labetalol Versus Hydralazine for Management of Severe Hypertension in Pregnancy
https://doi.org/10.1007/s13224-017-1053-9 ORIGINAL ARTICLE Comparison of Efficacy and Safety of Intravenous Labetalol Versus Hydralazine for Management of Severe Hypertension in Pregnancy Purvi Patel 1
Angina pectoris due to coronary atherosclerosis : Atenolol is indicated for the long term management of patients with angina pectoris.
Lonet Tablet Description Lonet contains Atenolol, a synthetic β1 selective (cardioselective) adrenoreceptor blocking agent without membrane stabilising or intrinsic sympathomimetic (partial agonist) activity.
Preeclampsia. &Eclampsia. Hypertensive Disorders of Pregnancy. What we need to know about. Hypertensive Disorders of Pregnancy.
Preeclampsia &Eclampsia Hypertensive Disorders of Pregnancy Barbara Koop MS, RNC-OB What we need to know about Hypertensive Disorders of Pregnancy Define clinical criteria for: Gestational hypertension,
JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
Difficult to Control HTN: It is not all the same. Structured approach to evaluation and treatment
Difficult to Control HTN: It is not all the same. Structured approach to evaluation and treatment Dmitri Vasin M.D. Nephrologist and ASH certified clinical hypertension specialist Bremerton, WA, USA Johnson
Research Article ISSN Vol 2/Issue 1/Jan-Mar 2012
A COMPARATIVE RANDOMISED CONTROLLED PARALLEL GROUP STUDY OF EFFICACY AND TOLERABILITY OF LABETALOL VERSUS METHYLDOPA IN THE TREATMENT OF NEW ONSET HYPERTENSION DURING PREGNANCY REENA VERMA 1, *KINGSHUK
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
Mercy San Juan Medical Center. Preeclampsia and Other Hypertensive Disorders of Pregnancy
SUBJECT: Preeclampsia and Other Hypertensive Disorders of Pregnancy DEPARTMENTS: FBC, Emergency Department PURPOSE: To outline the nursing management of inpatients who have preeclampsia or other hypertensive
Combination Therapy for Hypertension
Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP
Antihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
Cedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
PREGNANCY INDUCED HYPERTENSION; TO COMPARE EFFICACY OF METHYLDOPA AND LABETALOL IN MANAGEMENT
The Professional Medical Journal DOI: 10.17957/TPMJ/16.3489 ORIGINAL PROF-3489 PREGNANCY INDUCED HYPERTENSION; TO COMPARE EFFICACY OF METHYLDOPA AND LABETALOL IN MANAGEMENT naadiasharif@hotmail.com 1.
Hypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
Update in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
Hypertensive Crises. Controlling high blood pressure prevents disease. Recognition and Management of Acute Hypertensive Emergencies
Controlling high blood pressure prevents disease Recognition and Management of Acute Hypertensive Emergencies David idweiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Functional Genomics
Dr Narender Goel MD (Internal Medicine and Nephrology) Financial Disclosure: None, Conflict of Interest: None
Dr Narender Goel MD (Internal Medicine and Nephrology) drnarendergoel@gmail.com Financial Disclosure: None, Conflict of Interest: None 12 th December 2013, New York Visit us at: http://kidneyscience.info/